Reflux hyphema from transient hypotony after Ozurdex® in eyes with prior GATT

Tanenbaum, Rebecca E.; Xiao, Jason; Qiu, Mary

doi:10.1016/j.ajoc.2023.101939

Cited by 2 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Temporary visual blurring may occur post-injection, cautioning patients to refrain from driving until vision resolves. Repeated treatments with OZURDEX may predispose to cataract formation and increased eye pressure, necessitating ongoing monitoring by a healthcare provider [ 28 ]. Studies have demonstrated the effectiveness of OZURDEX in enhancing visual acuity and reducing CRT in patients with macular edema related to RVO.…”

Section: Reviewmentioning

confidence: 99%

Intravitreal OZURDEX vs. Intravitreal Bevacizumab for Diabetic Macular Edema: A Comprehensive Review

Jain,

Daigavane

2024

Cureus

View full text Add to dashboard Cite

This comprehensive review examines the efficacy, safety, and implications of intravitreal OZURDEX and intravitreal bevacizumab in treating diabetic macular edema (DME). DME is a common complication of diabetes mellitus and a leading cause of vision loss. OZURDEX, through sustained release of dexamethasone, targets inflammation and vascular permeability, while bevacizumab inhibits vascular endothelial growth factor (VEGF), reducing angiogenesis. However, differences in safety profiles exist, with OZURDEX associated with an increased risk of intraocular pressure elevation and cataract formation and bevacizumab potentially carrying systemic risks. The choice between these treatments should be individualized, considering patient preferences, ocular and systemic comorbidities, and cost-effectiveness. Collaboration among healthcare providers is essential for the comprehensive management of DME. Future research should focus on long-term comparative studies, predictors of treatment response, and exploration of novel therapeutic targets to optimize treatment outcomes for patients with DME.

show abstract

Section: Reviewmentioning

confidence: 99%

Intravitreal OZURDEX vs. Intravitreal Bevacizumab for Diabetic Macular Edema: A Comprehensive Review

Jain,

Daigavane

2024

Cureus

View full text Add to dashboard Cite

show abstract

Historical and Contemporary Debates in Schlemm’s Canal-Based MIGS

Chihara,

Hamanaka

2024

JCM

View full text Add to dashboard Cite

Glaucoma is one of the primary causes of blindness worldwide. Canal opening surgery, a type of minimally invasive glaucoma surgery (MIGS) applied in cases of mild to moderate glaucoma, has gained increasing popularity in recent years due to its efficacy in reducing the intraocular pressure, its safety profile, the simplicity of its technique, and the reduced likelihood of compromised vision. Nevertheless, the existing body of histopathological studies remains insufficient for a comprehensive understanding of post-surgical wound healing. Consequently, debates persist among researchers regarding the mechanism through which Schlemm’s canal opening surgery reduces the intraocular pressure, as well as the surgical techniques that may impact the outcomes and the factors influencing surgical success. As the history of MIGS is relatively short and lacks sufficient systemic reviews or meta-analyses evaluating the influence of individual factors, this review was conducted to illuminate the disparities in researchers’ opinions at the current stage of research.

show abstract

Reflux hyphema from transient hypotony after Ozurdex® in eyes with prior GATT

Cited by 2 publications

References 7 publications

Intravitreal OZURDEX vs. Intravitreal Bevacizumab for Diabetic Macular Edema: A Comprehensive Review

Intravitreal OZURDEX vs. Intravitreal Bevacizumab for Diabetic Macular Edema: A Comprehensive Review

Historical and Contemporary Debates in Schlemm’s Canal-Based MIGS

Contact Info

Product

Resources

About